Educating Patients on Adverse Effects Related to Talquetamab in MM
Expert perspectives on educating patients with multiple myeloma on adverse effects related to treatment with talquetamab.
EP: 1.Patient Scenario: A 63-Year-Old Man with Multiple Myeloma
EP: 2.Resources for Educating Patients with Myeloma
EP: 3.Patient Scenario Cont’d: Treatment in Late-Line Relapsed MM
EP: 4.Treatment Sequencing and the Role of Talquetamab in MM
Now Viewing
EP: 5.Educating Patients on Adverse Effects Related to Talquetamab in MM
EP: 6.Managing Talquetamab-Associated Toxicities in Patients with MM
EP: 7.The Role of a GPRC5D-Targeting Bispecific in Relapsed/Refractory MM
EP: 8.MM Treatment: Clinical Advice on the Care of Patients Receiving Talquetamab
EP: 9.Key Takeaways on Evolving Treatment Landscape in Multiple Myeloma
Recent Videos
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
Related Content
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
